|
|
|
|
|
|
|
|
|
|
|
05.10.26 - 14:03
|
GE HealthCare to Acquire SOFIE Biosciences, Establishing a ′Final Mile′ Footprint for PET Radiopharmaceutical Supply in the U.S. (Business Wire)
|
|
|
Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas
Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers
Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027...
|
|
|
|
|
29.09.26 - 13:06
|
Elucid Appoints Mark Miller as Chief Revenue Officer to Lead Commercial Expansion Ahead of BioIntegrated FFR-CT Launch (Business Wire)
|
|
|
Veteran cardiovascular imaging and diagnostics sales leader to drive go-to-market strategy as Elucid prepares for FDA clearance of FFR-CTBOSTON--(BUSINESS WIRE)--#YesCCT--Elucid, a medical technology company using AI-powered, clinically validated software to advance precision diagnosis of cardiovascular disease, today announced that Mark Miller has joined the company as chief revenue officer (CRO). Miller will sit on Elucid's leadership team and report directly to CEO Kelly Huang, PhD. He joins the company ahead of the launch of its comprehensive cardiovascular platform, which is comprised of its FDA-cleared Plaque-IQ™ and its BioIntegrated FFR-CT software, pending FDA clearance.
Miller has more than 25 years of experience building and scaling sales organizations across cardiovascular imaging, cardiac diagnostics, and AI-enabled clinical decision support, grounded in a clinical foundation in cardiopulmonary science. He spent a decade between GE Healthcare and Philips, selling directly into cardiology p...
|
|
|
28.09.26 - 15:03
|
Biodextris Appoints Clement Fourny as Chief Executive Officer (Business Wire)
|
|
|
Seasoned life sciences leader joins Laval-based CDMO to drive next phase of growthMONTREAL--(BUSINESS WIRE)--Biodextris, a Laval, Quebec based biologics contract development and manufacturing organization (CDMO) today announced the appointment of Clement Fourny as its Chief Executive Officer. Biodextris is known for its expertise working with complex biologics and Clement with over two decades of commercial and financial leadership experience across the life sciences and healthcare sectors, is ideally positioned to lead Biodextris into its next phase of growth.
Most recently, Clement served as Senior Vice President, Commercial at SmartLabs in Boston, where he led comprehensive commercial organization and spearheaded the launch of a new Custom Solutions division, securing landmark laboratory partnerships with biopharma companies across North America. Prior to SmartLabs, he served as General Manager, Commercial Operations & Strategy at Cytiva (formerly GE Healthcare Life Sciences), where he built deep exper...
|
|
|
|
|
|
|
22.09.26 - 23:30
|
GE HealthCare announces cash dividend increase for third quarter of 2026 (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.04 per share of Common Stock for the third quarter of 2026, an increase of 14% from the previous quarter. The dividend will be payable on November 13, 2026, to all shareholders of record as of October 23, 2026.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare...
|
|
|
22.09.26 - 22:06
|
GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortune 50 company, to its Board of Directors, effective January 4, 2027. Mr. Desroches brings more than 30 years of leadership experience across finance, governance, and large-scale technology and digital transformation.“Pascal is a highly respected executive and accomplished financial leader whose experience spans corporate strategy, capital deployment, and investor engagement,” said H. Lawrence Culp, Jr., Chairman of the Board of Directors, GE HealthCare. “His perspective will further strengthen our Board as we execute on our strategy to advance precision care, accelerate our next wave of innovation, and create long-term value for patients, customers, and shareholders.”Mr. Desroches has served as CFO of AT&T since 2021 and plans to retire from the company on December 31, 2026. Previously, he served as C...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
